Trial Profile
Efficacy of Evolocumab in patients with arteriosclerosis obliterans.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2018
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Arteriosclerosis obliterans; Dyslipidaemias
- Focus Therapeutic Use
- 04 Jun 2018 New trial record